McIlrath & Eck’s NeoGenomics NEO Stock Holding History

McIlrath & Eck’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-75	Closed	-$1K	–	859
2022 Q1	$1K	Hold	75	–	–	﹤0.01%	773
2021 Q4	$3K	Hold	75	–	–	﹤0.01%	698
2021 Q3	$4K	Hold	75	–	–	﹤0.01%	657
2021 Q2	$3K	Hold	75	–	–	﹤0.01%	695
2021 Q1	$4K	Hold	75	–	–	﹤0.01%	626
2020 Q4	$4K	Hold	75	–	–	﹤0.01%	566
2020 Q3	$3K	Hold	75	–	–	﹤0.01%	557
2020 Q2	$2K	Hold	75	–	–	﹤0.01%	596
2020 Q1	$2K	Buy	+75	New	+$2.25K	﹤0.01%	564

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

McIlrath & Eck's NEO Position: Q2 2022 in Review

McIlrath & Eck sold out of NeoGenomics (NEO) in Q2 2022, closing a stake of 75 shares — an estimated $1K sold.

McIlrath & Eck first reported a position in NEO in Q1 2020 and held it in 9 quarters. The position peaked at $4K in Q3 2021. 239 funds tracked by Wall St. Rank hold NEO as of Q2 2022.

McIlrath & Eck reported no remaining NeoGenomics position as of Q2 2022 after selling out during the quarter.
McIlrath & Eck sold 75 NeoGenomics shares in Q2 2022, an estimated $1K.
McIlrath & Eck first reported a position in NeoGenomics in Q1 2020 and held it in 9 quarters.
McIlrath & Eck's NeoGenomics position peaked at $4K in Q3 2021.
239 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2022.

Based on McIlrath & Eck's 13F filing for Q2 2022, filed 29 Jul 2022.